In a study published by van der Sluis et al in The New England Journal of Medicine, researchers sought to determine if adding the bispecific T-cell engager (BiTE) antibody blinatumomab to the Interfant-06 chemotherapy protocol—consecutive courses of protocol IB (cyclophosphamide, cytarabine, and mercaptopurine), MARMA (high-dose cytarabine, high-dose methotrexate, mercaptopurine, and asparaginase), OCTADAD (vincristine, dexamethasone, asparaginase, daunorubicin, thioguanine, cytarabine, and cyclophosphamide), and maintenance therapy (mercaptopurine and methotrexate)—improved outcomes among babies with KMT2A-rearranged acute lymphoblastic leukemia (ALL).
